Hua Hai Technology, a subsidiary of Huahai Pharmaceutical (600521.SH), passes on-site inspection by the US FDA.

News from the Securities Times app, Huahai Pharmaceutical (600521.SH) announced that its subsidiary Zhejiang Huahai Pharmaceutical Technology Co., Ltd. (referred to as "Huahai Technology") underwent an on-site supervision inspection by the US FDA from August 18, 2025 to August 22, 2025. The inspection scope covers the overall quality management system of the factory and oral solid dosage form products. Recently, the company received the on-site inspection report, which indicated that the production base of Huahai Technology meets the requirements of the US drug CGMP (current good manufacturing practice) and passed this on-site inspection.